In my last big post I was all fired up about the metabolic theory of cancer and my fire has only intensified. I’m so lucky that immediately on the heels of that post I was able to meet with the team at Care Oncology Clinic, a group that specializes in exactly this type of treatment intended to complement traditional therapies. Their protocol relies on the off-label effects of common medications. The same way I used to take benadryl for sleeping instead of allergy relief, they use metformin for cancer instead of diabetes.
They’ve received regulatory and ethical approval in the UK and are currently offering this treatment as part of a Phase 3 clinical trial to gain full FDA approval. This is Phase 3 because these drugs have already been proven safe (Phase 1) and effective (Phase 2).
Care is nonprofit and make their compounds and research completely open to the public. Best of all, while I was willing to fly to any of their UK, New Zealand, or US locations, they offer teleconsultations and are able to ship the medications to any location within those countries (thanks again, Hendriks!).
To sum up: Hooray! End of July when I’m traveling to the Mayo Clinic I’ll be able to pick up my first 3-month supply and will start the Care Oncology protocol in addition to my lorlatinib by 1 August.
Care Oncology Metabolic Protocol
The Care protocol is designed to shut down the various metabolic pathways I talked about in my previous post while supporting other functions. The drugs included are:
The very same drug diabetics take to lower blood sugar. I’m especially eager for this as it will allow me to start eating a bit more protein. Until now, I’ve had to limit my protein in addition to my carbs to keep my blood sugar low.
This will help reduce the fatty acid fuels available to cancer. As an added bonus, my cholesterol is through the roof secondary to the lorlatinib and my oncologist has wanted to put me on it, anyway.
A common antibiotic that works by interfering with the ability of bacteria to produce proteins that are critical to them. There’s evidence the same mechanism can block the metabolic pathways of cancer, as well.
- Mebendazole (alternating with Doxycycline)
An old-school anti-parasitic medication that blocks parasites’ ability to absorb sugar and does the same for cancer. It also inhibits pyruvate kinase, a key enzyme in the glycolytic pathway which is dominant in cancer cells
I can’t tell you how excited I am nor how eager to get my hands on these drugs. With the lorlatinib still working like a champ I feel even more confident in the chance to prolong my life many many years.
- Recently featured in The Economist with a great exposure on how research into these off-label drugs isn’t even supported by governments or non-profits.
- Many resources at the foundation that started it all and my new source for all cancer-related donations (scroll down)